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The present study demonstrates that repeated administra- 
tion of SKF-38393, a D,-dopamine agonist, is necessary for 
maximal behavioral supersensitivity of D,-dopamine receptor 
responses in neonatal 8-OHDA-lesioned rats, confirming 
earlier work. This repeated administration of SKF-38393, 
which is referred to as priming of D,-dopamine receptor re- 
sponses, resulted in a progressive increase in locomotor 
activity, as well as several other behaviors. This priming 
phenomenon lasted at least 8 months. Repeated adminis- 
tration of the D,-dopamine agonist LY-171555 also in- 
creased behavioral responses to the D,-dopamine agonist. 
However, previous administration of a D,-dopamine agonist 
was not necessary for priming of D,-dopamine receptor re- 
sponses, because D,-dopamine receptor priming could be 
produced in the presence of a D,-dopamine receptor antag- 
onist. Blockade of D,-dopamine receptors with SCH-23390 
prior to injection of SKF-38393 prevented the increasing re- 
sponsiveness following repeated administration of this D,- 
dopamine agonist. Selective neonatal destruction of dopa- 
mine-containing neurons produced the same result as did 
destruction of catecholamine-containing neurons, indicating 
that the noradrenergic system is not involved in this phe- 
nomenon. Priming of D,-dopamine receptor responses by 
repeated administration of SKF-38393 was not observed in 
unlesioned controls or in rats that received catecholamine- 
depleting lesions as adults. Repeated administration of sco- 
polamine also was able to prime behavioral responses to 
SKF-38393 in neonatal 6-OHDA-lesioned rats, indicating that 
endogenous release of dopamine can prime D,-dopamine 
receptor responses in neonatally lesioned rats. In addition, 
responses to indirect-acting agonists were enhanced in rats 
that had been primed with a D,-dopamine agonist when com- 
pared with responses in unprimed animals. Furthermore, re- 
peated microinjection of SKF-38393 into the nucleus accum- 
bens progressively increased locomotor activity, indicating 
that a local action of SKF-38393 is responsible for the priming 
of D,-dopamine receptor responses. Thus, priming of D,- 
dopamine receptor responsiveness in neonatal 6-OHDA-le- 
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sioned rats represents an example of a robust, chemically 
specific change in neural function that is relatively perma- 
nent. The potential relationship of this phenomenon to chron- 
ic drug treatment, permanent neural messages, and symp- 
toms in Lesch-Nyhan disease is discussed. 
The D,-dopamine agonist SKF-38393 does not produce the 
profound effects on behavior in normal rats that are observed 
after Dz- or mixed D,/D,-dopamine agonists (Stoof and Ke- 
babian, 1984; Breese et al., 1985a, b). However, following neo- 
natal, but not adult, 6-OHDA lesions, rats exhibit greater be- 
havioral supersensitivity to a D,-dopamine agonist than to a 
D2-dopamine agonist (Breese et al., 1985a, b, 1986). Breese et 
al. (1985b) reported that it was necessary to administer the D,- 
dopamine agonist SKF-38393 repeatedly in order to obtain 
maximal supersensitivity of the D,-dopamine receptor subtype 
in neonatal 6-OHDA-lesioned rats. This progressive change in 
sensitivity with repeated treatment was referred to as “priming.” 
Repeated administration ofthe D,-dopamine agonist LY- 17 1555 
(Tsuruta et al., I98 1) was also capable of enhancing the effect 
of subsequent administration of SKF-38393, but not to the 
degree seen after repeated doses of SKF-38393 (Breese et al., 
1985b). Recently, Morelli et al. (1987) found that the dopamine 
agonist-induced rotation observed in rats with unilateral 
6-OHDA lesions was not seen on the first administration of a 
D,-dopamine agonist. While first suggesting that previous ac- 
tivation of the D,-dopamine receptor was essential for dem- 
onstration ofD,-dopamine supersensitivity (Morelli et al., 1987) 
these workers later reported that either D,- or Dz-dopamine 
agonists could prime the D,-dopamine receptor response after 
unilateral 6-OHDA lesions of the nigrostriatal pathway (Morelli 
and Di Chiara, 1987). The increasing sensitivity ofD,-dopamine 
receptors following repeated exposure to dopamine agonists sug- 
gests that the D,-dopamine receptor may possess a degree of 
plasticity that could have important implications for under- 
standing long-term changes in behavior associated with repeated 
drug use or the basis of symptoms of childhood disorders sec- 
ondary to a central dopamine deficiency. 
In the original description of priming, the neonatal 6-OHDA- 
lesioned rats received the mixed D,/D,-dopamine receptor ag- 
onist, L-DOPA, prior to the administration ofSKF-38393 (Breese 
et al., 1985b). Therefore, it was important to determine whether 
the priming of the D,-dopamine receptor response in neonatal 
6-OHDA-lesioned rats could be obtained without previous ex- 
posure to a dopamine agonist that influenced D,-dopamine re- 
ceptors. Additionally, a variety of other aspects concerning this 
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phenomenon needed to be addressed. For example, the duration 
of the effect had not been studied. Since both noradrenergic and 
dopaminergic neurons were destroyed in the rats used in early 
investigations, another concern was the contribution the absence 
of noradrenergic fibers might be having to the priming phenom- 
enon. It was also important to know whether a classical con- 
ditioning phenomenon, whereby drug administration is asso- 
ciated with the testing chamber, could account for the priming 
effect, as has been observed for behavioral sensitization to stim- 
ulant drugs on some (Tilson and Rech, 1973) though not all 
(Robinson, 1984) occasions. The initial work on priming of D,- 
dopamine receptors measured activity (Breese et al., 1985b). It 
was not determined whether other behaviors associated with 
D,-dopamine receptors (Breese et al., 1985a) were enhanced 
with repeated dosing of the D,-dopamine agonist. In addition, 
it is important to know whether endogenous release ofdopamine 
could prime the D,-dopamine receptor response and if priming 
could be elicited by stimulation of an isolated brain region or 
whether more integrated CNS function was required. The func- 
tion of the present investigation was to answer these questions 
about the increasing supersensitivity of D,-dopamine receptors 
in neonatal 6-OHDA-lesioned rats repeatedly dosed with D,- 
or D2-dopamine agonists. Results from these rats were com- 
pared with those from adult 6-OHDA-lesioned and unlesioned 
control rats when appropriate. 
Materials and Methods 
General 
Adult male and female Sprague-Dawley rats were obtained from Charles 
River Laboratories Inc. (Raleigh, NC). These animals were treated in- 
tracistemally with 6-OHDA (200 pg free base/25 ~1) 30 min after 50 
mg’kg pargyline. One week later, they received an additional 200 /~g of 
6-OHDA intracistemallv (Breese and Traylor, 1970). All animals were 
allowed at least 2 weeks to recover from the adipsia and aphagia that 
can follow 6-OHDA lesioning of catecholamine-containing neurons 
(Breese et al., 1975). In addition to these adult rats, pregnant Sprague- 
Dawley rats obtained from Charles River Laboratories were individually 
housed with Wayne Lab Blox laboratory chow, and water was available 
ad lib until delivery. At day 3 after delivery, each neonate was anes- 
thetized with ether and injected intracisternally with 100 fig (free base) 
of 6-OHDA hydrobromide (Regis Chemical Co., Chicago) dissolved in 
10 ~1 of saline (Breese et al., 1975). Neonates of both sexes were then 
returned to their mothers with liter size limited to 10. Some neonates 
were pretreated with 20 mg/kg desipramine (Regis Chemical Co.) 1 hr 
prior to 6-OHDA injection to restrict the neuronal damage to dopamine- 
containing neurons (Smith et al., 1973). Rats treated with 6-OHDA or 
saline neonatally were weaned at day 30 and testing was begun at 40- 
50 d of age. 
Drugs 
The 6-OHDA hydrobromide (Sigma Chemical Co., St. Louis) was dis- 
solved in saline containing 0.5% ascorbic acid and administered intra- 
cisternally. SKF-38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-I-phenyl-lH- 
3-benazepine HCl; Smith Kline and French Laboratories, Philadephia), 
theophylline (Sigma), scopolamine hydrochloride (Sigma), d-amphet- 
amine sulfate (Sigma), pargyline hydrochloride (Sigma), and LY- 17 1555 
[trans-(-)-4aR-4,4a,5,6,7,8,8a,9-octahydro-5-propyl-lH-Pyrazo- 
10(3,4)] quinoline HCl; Eli Lilly Co., Indianapolis, IN] were dissolved 
in saline and administered intraperitoneally or by microinjection into 
the nucleus accumbens. Haloperiodol (McNeil Laboratories, Fort Wash- 
ington, PA) was dissolved in 0.1% tartaric acid and administered in- 
traperitoneally. 
an agonist was administered, observations were made for 1 min ofevery 
10 min oeriod for 2 hr. Each 1 min ueriod was divided into four 15 set 
intervals, and behaviors from a checklist were scored for occurrence in 
each of the 15 set periods. Each behavior had a maximum score of 4 
for the 1 min observation period x 12 observation periods, for a total 
of 48 (see Breese et al., 1985a). Behavior is reported as a percentage of 
the total possible. Behaviors monitored included sniffing, rearing, 
grooming, head nodding, locomotion, taffy pulling (repeated movement 
of the paws toward and then away from the snout), paw treading, licking, 
jumping, digging, eating wood chips, and self-biting (biting an extremity 
without breaking the skin). SMB was scored if biting resulted in a break 
in the skin, and SCH-23390 was administered at that point to block 
the SMB. 
Activity. Activity was measured by placing rats in a circular photocell 
activity monitor (Hollister et al., 1974). Six photo sensors were placed 
about the periphery, and counts from each sensor were collected by a 
microcomputer and recorded at 10 min intervals for 150 min. Rats 
were habituated to the activity chamber for 1 hr before administration 
of the dopamine agonist. 
Microinjection procedure 
Under Nembutal anesthesia (30 mg’kg for neonatally lesioned animals 
and 50 mg’kg for adult 6-OHDA-lesioned animals and unlesioned con- 
trols), animals were prepared for microinjection by implanting a 26 
gauge cannula bilaterally aimed at a site 1.5 mm above the nucleus 
accumbens (AP = 2.2 mm, L = 1.4 mm, D = 4.0 mm; Paxinos and 
Watson, 1982). At least a week was allowed for recovery from the 
imnlant suraerv before behavioral testing. Microiniection of SKF-38393 
(1 ;g in 0.5 ;I of saline) was made over a-5 min period with the injection 
cannulae left in place for an additional 1 min following the injection. 
The injection cannula was 33 gauge and extended 1.5 mm below the 
tip of each guide cannula. Fluid was pumped by a Sage syringe pump 
through a 20-30 cm length of PE-10 tubing (see Breese et al., 1987). 
The location of each cannula was verified at the end of the study by 
examination of frozen sections. 
Monoamine assessment 
For catecholamine depleted animals that received drug microinjection 
into nucleus accumbens, the dopamine levels were determined in ol- 
factory tubercles. Nucleus accumbens or striatal tissue was not available 
following histological verification of the microinjection sites. For these 
rats, the olfactory tubercles were dissected from the brain, weighed and 
placed on dry ice. Samples were stored at - 70” C until monoamines were 
determined using reverse-phase high performance liquid chromatog- 
raphy with electrochemical detection (Kilts et al., 198 1). The remaining 
catecholamine depleted animals were retained and used in other studies 
(Duncan et al., 1987; Criswell et al., 1988). For rats with specific do- 
pamine depleting lesions (desipramine plus 6-OHDA), samples were 
taken from nucleus accumbens, caudate, olfactory tubercles, and hip- 
pocampus. Dopamine and norepinephrine were determined for hip- 
pocampus by the method of Widerlov et al. (1982). Levels of dopamine, 
5-HT and their major metabolites were obtained for the remaining 
specific sites by the method of Kilts et al. (198 1). Norepinephrine was 
determined in brain remaining after dissection of specific regions, using 
the procedure of Breese and Traylor (1970, 1972). 
Statistical evaluation 
Previous work has shown that there are no significant behavioral dif- 
ferences between male and female 6-OHDA-lesioned rats (Breese et al., 
1984). Therefore, data were collapsed across sexes for analysis. For 
behavioral observations, each behavior was analyzed separately using 
a l-factor repeated-measures ANOVA. The scores analyzed were the 
percentage of 15 set observation periods during which a given behavior 
occurred (Breese et al.. 1984: Criswell et al.. 1988). Activitv was analvzed 
by summing the activity connts for 150 min and’performing a repeated- 
measures ANOVA on the totals. When the ANOVA showed a significant 
overall effect. individual comoarisons among means were made with 
Evaluation of behavior and activity the Tukey HSD or Dunnett test (Winer, 197 1,. Progressive increases or decreases in activity over repeated testing sessions were assessed by 
Behaviovul observations. Rats were placed in clear plastic cages (23 x linear trend analysis (Winer, 197 1). A significant linear trend was in- 
44 cm) for 60 min before administration of a dopamine agonist. Once terpreted as indicating a progressive change over time. 
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Results 
Measurement of activity and other behaviors following 
repeated administration of SKF-38393 to neonatal 
6-OHDA-lesioned rats 
The progressive increase in activity following repeated SKF- 
38393 administration to neonatal 6-OHDA-lesioned rats is 
shown in Figure 1. Neither adult 6-OHDA-lesioned nor unle- 
sioned control animals showed the progressive increase in ac- 
tivity levels with repeated administration of SKF-38393 ob- 
served in neonatally lesioned animals (Fig. 1). On retesting a 
group of 4 animals with 3 mg/kg SKF-38393 6 months after 
their last drug treatment, they showed a mean activity level of 
18,752 + 5209, which was similar to the rate observed 1 week 
after the last priming dose of the D,-dopamine agonist (19,2 16 
+ 4386 counts/l50 min; p > 0.1). Priming was not observed 
in a group of rats that received 5 weekly injections of saline. 
The increased sensitivity to SKF-38393 following multiple 
administrations to neonatal 6-OHDA-lesioned rats also oc- 
curred in an observational setting (Fig. 2). There was a pro- 
gressive change in locomotor activity, rearing, sniffing, digging, 
grooming, and paw treading following repeated administration 
of SKF-38393 (Fig. 2). None of these behavioral changes oc- 
curred in nonlesioned controls, adult-lesioned animals, or neo- 
natally lesioned animals receiving repeated saline injections (see 
Fig. 2). An unexpected finding was the progressive decrease in 
selected behaviors (locomotion, sniffing, and rearing) during re- 
peated administration of SKF-38393 to unlesioned animals (see 
Fig. 2). An expanded listing of behaviors after repeated admin- 
istration of SKF-38393 to neonatal 6-OHDA-lesioned rats is 
summarized in Table 1. Greater than 90% depletion of dopa- 
mine was obtained in the olfactory tubercles of both the adult 
and neonatal 6-OHDA-lesioned animals (Fig. 1 legend). 
Efect of environment on the progressive increase in responding 
after repeated administration of SKF-38393 
The animals that received their initial 5 SKF-38393 injections 
in an environment different from the activity cages (i.e., the 
cages used for open-field observation) showed high levels of 
activity after the sixth injection when first placed in the activity 
test chamber (see Table 2A). This increase was comparable to 
that seen after multiple treatments in the activity cages (Fig. 1). 
Increased behavioral sensitivity to SKF-38393 was also ob- 
served when neonatally lesioned animals were treated for 5 trials 
in the activity chambers and subsequently tested in the obser- 
vation chambers on trial 6 (Table 2B). It is also important to 
note that the activity response to the first dose of SKF-38393 
after animals had been tested for 5 trials with saline injections 
did not differ from that of rats naive to the activity chamber 
(Fig. 1 legend). 
Investigation of the priming of D,-dopamine receptor 
responses in rats with preferential reduction of dopamine 
Repeated administration ofthe D,-dopamine agonist SKF-38393 
to rats treated neonatally to destroy selectively only dopamine- 
containing neurons (Smith et al., 1973) also was found to pro- 
duce a progressive increase in activity (Fig. 3), similar to that 
seen in rats that had both dopamine- and norepinephrine-con- 
taining fibers destroyed (Fig. 1). Behavioral responses were also 
increased in this treatment group after repeated administration 
of SKF-38393 (Table 3). Documentation of the effectiveness of 
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Figure I. Locomotor activity following repeated weekly administra- 
tion of the D,-dopamine agonist SKF-38393 (A) or saline (B) to unle- 
sioned, neonatal and adult 6-OHDA-lesioned rats. All animals were 
tested as adults. Dose refers to treatments with either saline or SKF- 
38393 (3 mg/kg, i.p.) at 1 week intervals. When SKF-38393 was ad- 
ministered for the first time to the neonatal 6-OHDA-lesioned rats 
following the 5 saline injections in B, the activity response was 4545 + 
756 counts/l 50 min -C SEM @ > 0.1 compared with dose 1 to neonatal 
6-OHDA-lesioned rats in A). The linear trend for increases in loco- 
motion with repeated administration ofSKF-38393 to neonate 6-OHDA- 
lesioned rats was significant @ i 0.01). There were no other significant 
linear trends (p > 0.1). Dopamine content of olfactory tubercles was 
6.0 * 0.3 ng’mg protein in control animals, 0.4 i 0.1 ng/mg protein 
in neonatal 6-OHDA-lesioned rats, and 0.3 f 0.05 ng/mg protein in 
adult 6-OHDA-lesioned rats. Depletion in the olfactory tubercles was 
93% in neonatally treated animals and 96.5% in adult treated animals 
compared with controls. *p < 0.05 compared with day 1; #p < 0.05 
compared with unlesioned controls. 
the 6-OHDA treatment to reduce only dopamine is provided 
in the legend of Figure 3. 
Investigation of the possible involvement of D,-dopamine 
receptors in the priming of D,-dopamine receptor responses 
When the D,-dopamine antagonist haloperidol was coadmin- 
istered with the D,-dopamine agonist, the SKF-38393-induced 
activity response did not differ from the response observed in 
the absence of haloperidol (Fig. 4). On the other hand, prior 
administration ofthe D,-dopamine antagonist, SCH-23390 (Io- 
rio et al., 1983), antagonized the response to SKF-38393 and 
prevented the priming of the D,-dopamine receptor response 
(Fig. 4). When prior administration of SCH-23390 was halted, 
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Figure 2. Behavioral changes follow- 
ing repeated weekly administration of ii 
the D,-dopamine agonist SKF-38393. 
r 
NEO-SKF, AD-SKF, and CON-SKF z 
refer to SKF-38393 administration to E 
neonatal 6-OHDA-lesioned, to adult 
6-OHDA-lesioned, and to unlesioned 
rats, respectively; NEO-SAL, AD-SAL, 
CON-SAL refer to saline administra- 
tion to these latter groups. Dose refers 
to the weekly administration of SKF- 
38393 (3 mg/kg) for 5 weeks. See Ma- 
terials and Methods for definition of 
percent of time. NEO-SKF animals 
showed significant linear trends for in- 
creasing levels of locomotor activity, 
rearing and sniffing, while CON-SKF 
animals showed significant linear trends 
for decreases in these behaviors with 
successive doses. *p < 0.05 compared 









subsequent administration of SKF-38393 caused a progressive 
increase in responding, demonstrating the ability of these rats 
to manifest priming of the D,-dopamine receptor response (Fig. 
4). 
was considerable variability in the degree to which the LY- 
17 1555 would alter the response to a subsequent dose of SKF- 
38393. 
Repeated administration of the selective D,-dopamine ago- Examination of priming of D,-dopamine receptors following 
nist LY-171555 did not result in a significant increase in the microinjection of SKF-38393 into the nucleus accumbens 
sensitivity to the D,-dopamine agonist but did result in an in- A progressive increase in activity was observed following re- 
crease in the subsequent response to a D,-dopamine agonist peated microinjection of 1 pg of SKF-38393 into the nucleus 
(Table 4). The magnitude of the increase in responsiveness to accumbens of neonatal 6-OHDA-lesioned, but not of nonle- 
SKF-38393 after LY- 17 1555 was less than that seen after SKF- sioned control, animals. This increased activity level observed 













(n = 9) 
Percentage incidence with SKF-38393 
Dose 1 Dose 5 or 60 
Control 6-OHDA Control 6-OHDA 
Quiet 69 + 6 22 + 4c 54+ 10 54 _+ 9 7 + 4°C 
Locomotion 2*1 9 + 2c 5+2 1 f  lh 52 zk lob,< 
Sniffing 20 + 6 55 + 6< 40 f  9 24 f  8” 18 f  6”< 
Rearing 6t2 30 * 5= 10 f  4 11 2 5h 48 + 10”c 
Paw treading o+o Ok0 13 + 8 Ok0 12 f  I 
Grooming 16 f  3 36 + 4= 5 + lc 29 + 6c 19 * 7h 
Digging Ok0 4fl 3*3 1+1 36 + 12”c 
Cage licking Ok0 Ok0 0.4 k 0.3 Ok0 2&2 
Taffy pulling Ok0 oto 3?2 o*o 0.2 f  0.0 
Self-biting Ok0 Ok0 4?2 o-+0 Ok-0 
a There are I3 rats in Dose 1 group data and 10 rats in the Dose 5 or 6 group data. SIW-38393 (3 n&kg) was administered 
5 or 6 times at weekly intervals and behavioral responses noted as described in Materials and Methods. 
h p < 0.05 compared with Dose 1 response for that drug. 
‘p < 0.05 compared with saline. 
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TEST SESSIONS 
Figure 3. Effect of repeated administration of SKF-38393 on activity 
level in rats with selective neonatal destruction of dopamine-containing 
neurons. The linear trend for increased responding with repeated admin- 
istration was significant (p < 0.01). Monoamine concentrations in 
6-OHDA-lesioned rats treated to reduce only dopamine were as follows: 
Dopamine was reduced in olfactory tubercles from 24.90 f  1.30 ng/ 
mg protein to 2.8 -t 0.6 ng/mg protein (89%). Dopamine was reduced 
from 65.6 f  3.9 ng/m’g and 56.5 ? 8.4 &kg protein, in the nucleus 
accumbens or caudate respectively in controls to no detectable content 
of dopamine (>99% depletion) in lesioned animals. Norepinephrine 
levels were not significantly changed (3% increase in hippocampus from 
11.6 + 1.9 to 12.0 f  2.0 ng/mg protein and 10% depletion in the rest 
of the brain from 65.6 f  3.0 to 58.0 + 3.0 ng/mg protein; p z 0.1). 
5-HT was increased in 6-OHDA-lesioned rats from 3.6 f  0.2 (control) 
to 12.6 + 0.4 ng/mg protein in the caudate nucleus (p < 0.05) but was 
unchanged in nucleus accumbens and olfactory tubercles (4.2 f  0.5 vs 
4.8 + 0.5 and 7.2 + 0.3 vs 8.2 f  0.8 ng/mg protein, respectively; p > 
0.05) in control and lesioned rats. *p < 0.05 compared with the first 
dose. 
Table 2. Effect of environment on subsequent responses to D,- 
dopamine agonist administration 





(counts/l 50 min f  SEM) 
2442 +- 760 
19,698 ? 5890”.“ 
B. Behavioral testing in open field after priming in activity monitors’ 
SKF-38393 
Behavior Dose 1 Dose 6 
Quiet 75.0 + 8.0 25.1 + 12.oe 
Locomotion 5.6 k 4.8 26.2 f  7.2’ 
Sniffing 22.9 f  8.9 11.7 + 6.1e 
Rearing 7.3 f  5.2 38.3 f  13.9’ 
Paw treading 0.0 f  0.0 15.4 + 14.9 
Grooming 7.0 + 2.0 20.0 k 5.oe 
Digging 0.0 + 0.0 19.0 f  15.0 
a Activity counts were recorded in a circular activity chamber. The Dose 1 group 
had not previously received SKF-38393, while the Dose 6 group had received 5 
previous injections ofSKF-38393 in a different environmental setting (behavioral 
observation cages). 
h p < 0.01 compared with dose 1. 
r p z 0.1 compared with dose 6 in rats dosed only in activity cages. 
d Neonatal 6-OHDA-lesioned animals were injected with 3 mg/kg of SKF-38393, 
placed in clear plastic cages and observed for 2 hr. The Day 1 group had not 
previously received SKF-38393, while the Day 6 group had received 5 injections 
of SKF-38393 in a different environmental setting (circular activity chamber). 
Numbers represent the precent of time that the animals engaged in the listed 
behaviors. The values on day 6 agree favorably with those in Table 1. There were 
6 rats in each group. 
e p < 0.05 compared with dose 1 in the same environment. 
El DOSE 4 
DOSE 5 
- . 
LINE HkO SCH-i3390 
Figure 4. Priming in neonatal 6-OHDA-lesioned rats by SKF-38393 
in the presence of haloperidol or SCH-23390. Neonatal 6-OHDA-le- 
sioned rats were treated with the Dz-dopamine antagonist haloperidol 
(HALO; 0.5 mg/kg) or the D,-dopamine antagonist SCH-23390 (0.3 
mg/kg) or saline 15 min prior to receiving 3 mg/kg of the D,-dopamine 
agonist SKF-38393. A minimum of 4 d was allowed between successive 
treatments. No SCH-23390 was given prior to the SKF-38393 on the 
last 2 testing sessions. The linear trend for increased locomotor activity 
was significant in both the saline and haloperidol-pretreated group (p 
< 0.01) but not in the SCH-23390 pretreated group 0, > 0.1). *p < 
0.05 compared with day 1. 
roughly equivalent to the response seen after systemically ad- 
ministered SKF-38393 (Fig. 5). While there was an apparent 
further increase in responsiveness observed with the repeated 
systemic injection of SKF-38393 in the rats repeatedly treated 
centrally with SKF-38393 (Fig. 5), this change did not reach 
statistical significance when day 1 response was compared with 
that produced on day 3 (p < 0.1). 
Evaluation of the ability of indirect-acting dopamine agonists 
to prime the D,-dopamine receptor response 
Previous data indicate that scopolamine and theophylline in- 
crease the activity level in 6-OHDA-lesioned rats; this response 
is dependent upon endogenous catecholamine release (Ondrusek 
Table 3. Behavioral responses at dose 1 and dose 5 following 
repeated weekly administration of the D,-dopamine agonist SKF- 
38393 to rats with neonatal lesions to dopamine-containing neurons 
Behavior 
Saline 
(n = 9) 
Percent incidence with 
SKF-38393 
Dose 1 Dose 5 
Quiet 26& 12 9-c4 0 + o* 
Locomotion 32 + 8 38? 11 59 f  106 
Sniffing 72 f  12 75 f  11 86 * 4 
Rearing 43+ 13 46 f  19 60+ 10 
Paw treading 6*3 o-to 35 + 100,b 
Grooming 5*1 24 f  lb 24 f  8b 
Digging Ok0 l&l 30 + 8a,b 
Cage licking Ok0 Ok0 oio 
Taffy pulling Ok0 Ok0 13 i 8 
Self-biting O&O o-to 4f4 
Rats were treated as neonates to reduce only brain dopamine (see Materials and 
Methods). When adult, rats were given 5 doses of SKF-38393 (3 mg/kg) at weekly 
intervals and behavior was observed in the open-field containers. Representative 
results from days 1 and 5 are presented. The saline group includes 9 rats, dose 1 
includes 6 rats and dose 5 includes 10 rats. Values for control rats after 1 and 5 
doses of SKF-38393 are given in Table 1. 
“p < 0.05 compared with dose 1. 
hp < 0.05 compared with saline. 
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0 
zx:f neonate neonate central systemic 
Figure 5. Activity response after repeated microinjection of 1 pg of 
SKF-38393 into the nucleus accumbens (central) of neonatal 6-OHDA- 
lesioned rats (neonate) or unlesioned control (control) animals followed 
by systemic administration (systemic) of SKF-38393 to neonatally le- 
sioned rats or to unlesioned control animals. Following the 3 microin- 
jections of SKF-38393 into the nucleus accumbens (central), subsequent 
systemic doses (systemic) of SKF-38393 (3 mg/kg, i.p.) were adminis- 
tered to the groups that received microinjections into the nucleus ac- 
cumbens. Treatments (Dose) were at 1 week intervals. There are at least 
5 rats in each group. *p < 0.05 compared with saline; #p < 0.05 
compared with naive animals. 
et al., 198 1; Cfiswell et al., 1988). Therefore, we chose to use 
these indirect-acting dopamine agonists to see if endogenous 
release of dopamine would prime D,-dopamine receptor re- 
sponses. In initial experiments, scopolamine and theophylline 
were repeatedly administered to neonatal 6-OHDA-lesioned rats 
at weekly intervals for 3 doses (Fig. 6). Following this treatment, 
the response to SKF-38393 was enhanced in the rats that re- 
ceived scopolamine (Fig. 6). There was a strong tendency for 
the response to be elevated after theophylline, but this did not 
reach statistical significance (Fig. 6). 
Efect of previous priming of D,-dopamine receptor responses 
on the responses to indirect-acting dopamine agonists 
Previous priming of the D,-dopamine receptor response with 
SKF-38393 resulted in an increased activity level following 
administration of theophylline or scopolamine (Fig. 7). Fur- 
thermore, the decreased ability of d-amphetamine to stimulate 
locomotor activity after 6-OHDA lesions was partially reversed 
by priming of the D,-dopamine receptor response (Fig. 7). 
Table 4. Effect of repeated administration of LY-171555 on 
subsequent response to NW-38393 
Dopamine agonist No. of 
dose0 rats tested 
Activity response 
(counts/ 150 min * 
SEM) 
LY-171555-l 10 7282 f  1583 
LY-171555-2 10 9353 + 1665 
LY-171555-3 10 10,473 + 1916 
SKF-38393- 1 10 13,710 +- 4483h 
SKF-38393-2 6 15,732 k 6076h 
0 Animals received LY- 17 1555 (1 mg/kg) doses at weekly intervals. After 3 doses 
of LY- I7 1555, rats were given SKF-38393 (3 mg/kg). The responses to different 
doses of LY- 17 1555 do not differ (p > 0.1). The first dose of SKF-38393 produced 
an activity response of 2894 + 980 counts/l 50 min in a saline-treated group. 
bp < 0.01 compared with dose I of SKF-38393 in naive 6-OHDA-lesioned 
neonates. 
Figure 6. Effect of repeated administration of theophylline and sco- 
polamine on the subsequent activity response to SKF-38393. A, The 
doses of theophylline (THEO; 10 mg/kg, i.p.) and scopolamine (XOP; 
0.5 mg/kg, i.p.) were administered at weekly intervals for 3 weeks and 
activity was measured. B, One week after the third dose of scopolamine 
(s) or theophylline (7) SKF-38393 (3 mg/kg) was administered and 
responses to SKF-38393 were compared with responses from naive 
control (C) animals. *p < 0.05 compared with response in saline; #p 
< 0.05 compared with response in naive rats. 
Discussion 
As previously reported (Breese et al., 1985b), repeated weekly 
administration of the D,-dopamine agonist SKF-38393 to 
neonatal 6-OHDA-lesioned rats resulted in a rapidly escalating 
activity level that peaked after 3-5 treatments. Because 
SCH-23390 prevented priming of the D,-dopamine receptor 
response, this priming phenomenon cannot be associated with 
a nonspecific action of SKF-38393. Priming of the D,-dopamine 
receptor response appears to be permanent with supersensitive 
behavioral responses still present 6 months after the last priming 
session. At present, we do not know whether the time between 
treatments is an important determinant of priming as it is in 
behavioral sensitization to amphetamine (Robinson and Becker, 













scopolamine theophylline amphetamine 
Figure 7. Administration of scopolamine, theophylline, and d-am- 
phetamine to rats with and without previous priming of D,-dopamine 
receptor responses. Control refers to rats, not lesions; unprimed refers 
to naive neonatal 6-OHDA-lesioned rats; primed refers to rats that 
received 5 previous treatments of SKF-38393 (3 mg/kg) at weekly in- 
tervals prior to receiving the indirect dopamine agonists. The i.p. dose 
for scopolamine was 0.5 mg/kg, for theophylline was 10 mg/kg, and for 
d-amphetamine was 1 mg/kg. *p < 0.05 compared with response in 
unlesioned controls; #p < 0.05 compared with response in unprimed 
animals. 
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single large dose of L-DOPA did not produce a significant amount 
of priming (Breese et al., 1985a). This suggests that a larger dose 
of SKF-38393 would not greatly facilitate this phenomenon. 
These variables will be the focus of future investigations. 
Priming of the D,-dopamine receptor response was also re- 
flected by an increase in the frequency of several other behaviors 
elicited by SKF-38393, including rearing, sniffing, grooming, 
digging, and paw treading. The behavioral responses to SKF- 
38393 in neonatal 6-OHDA-lesioned rats have been summa- 
rized previously (Breese et al., 1985a). In general, there is a 
reasonable congruence between the incidence with which a be- 
havior was observed in the present study and that noted in our 
previous report, except for 2 behaviors-taffy pulling and self- 
biting. In the present study, the incidence of these latter behav- 
iors after SKF-38393 was considerably lower than previously 
reported after SKF-38393 (Breese et al., 1985a). A difference 
between these studies is that the rats in the present investigation 
were not treated with L-DOPA prior to receiving the multiple 
SKF-38393 treatment (Breese et al., 1985b). Because these be- 
haviors are frequently observed after L-DOPA administration 
to neonatal 6-OHDA-lesioned rats (Breese et al., 1985a), it is 
possible that taffy pulling and self-biting require activation of 
both D,- and D,-dopamine receptors for a maximal behavioral 
expression. We have previously reported the importance of D,/ 
Dz-dopamine receptor activation to produce a maximal inci- 
dence of self-mutilatory behavior in the neonatal 6-OHDA- 
lesioned rat, even though D,-dopamine receptors are critical for 
this behavior to occur (Breese et al., 1985a). 
Previous work has shown that both neonatal and adult 
6-OHDA-lesioned animals are supersensitive to the behavioral 
effects of the D,-dopamine agonist LY- 17 1555, with adult-le- 
sioned animals exhibiting significantly more behavioral acti- 
vation than the neonatally lesioned animals after this drug (Breese 
et al., 1985a, b). In agreement with earlier work (Breese et al., 
1985b), the supersensitivity to a D,-dopamine agonist was found 
to be present from the first treatment and did not increase with 
repeated dosing in the neonatal 6-OHDA-lesioned rat. While 
priming of the D,-dopamine receptor response was not observed 
with repeated administration of the D,-dopamine agonist, this 
treatment resulted in priming of responses to the D,-dopamine 
agonist in neonatal 6-OHDA-lesioned rats. In our earlier stud- 
ies, the animals received one dose ofthe mixed D,/D,-dopamine 
agonist, L-DOPA, prior to investigating the priming response 
to D,-dopamine receptor activation (Breese et al., 1985b). Mo- 
relli et al. (1987) recently reported that prior stimulation of the 
D,-dopamine receptor was required for subsequent supersen- 
sitivity to D,-dopamine agonists in adult unilaterally lesioned 
rats; however, Morelli and Di Chiara (1987) subsequently re- 
ported that both D,- and D,-dopamine agonists can prime D,- 
dopamine receptors in animals with unilateral 6-OHDA lesions 
of the nigrostriatal pathway. In the present study, priming of 
the D,-dopamine receptor response was observed in drug-naive 
neonatal 6-OHDA-lesioned animals irrespective of whether or 
not the D,-dopamine antagonist haloperidol was administered 
concurrently with the D,-dopamine agonist. Thus, even though 
D,-dopamine receptor activation can contribute to priming of 
D,-dopamine receptors, the present results clearly indicate that 
D,-dopamine receptor stimulation is not necessary for induction 
or expression of behavioral supersensitivity to D,-dopamine 
agonists in neonatal 6-OHDA-lesioned animals. Priming of the 
D,-dopamine receptor response was also observed in animals 
with selective destruction of dopamine-containing neurons. This 
indicates that absence of other catecholamine-containing neu- 
rons is not necessary for priming to occur. The behavioral profile 
of these selectively lesioned animals differed slightly from that 
of animals with nonselective catecholamine depletion, which is 
consistent with previous literature (Breese et al., 1984). 
The critical importance of the age at which the 6-OHDA 
lesion is made to the subsequent response seen to dopamine 
agonists has been described in previous work (Breese and Tray- 
lor, 1972; Breese et al., 1984). A relatively selective supersen- 
sitivity to D,-dopamine agonists is observed in neonatal 
6-OHDA-lesioned rats, whereas adult 6-OHDA-lesioned rats 
exhibit a greater sensitivity to D,-dopamine agonists (Breese et 
al., 1985b). Neonatal 6-OHDA-lesioned rats do not exhibit the 
period of adipsia and aphagia associated with adult 6-OHDA 
lesions, even though they have lower body weights following 
the lesion (Breese and Traylor, 1972). Additionally, neonatally 
lesioned rats are subsensitive to the immobility produced by 
both D,- and D,-dopamine antagonists when compared with 
rats lesioned as adults (Bruno et al., 1985; Duncan et al., 1987), 
and have an elevated content of 5-HT, a change not seen in 
adult-lesioned rats (Breese et al., 1984). In the present study, 
animals that received 6-OHDA lesions as adults did not show 
a progressive increase in responding to repeated administration 
of SKF-38393 as did the neonatally lesioned rats. Such results 
provide further evidence that adaptive variables in the neona- 
tally lesioned rat differ from those seen in rats lesioned as adults. 
Scopolamine and theophylline can produce enhanced activity 
levels in 6-OHDA-lesioned rats, and this response appears to 
depend on catecholamine release from remaining neurons (On- 
drusek et al., 198 1; Criswell et al., 1988). In neonatal 6-OHDA- 
lesioned rats, the response to the first dose of these compounds 
was less than that seen after the compounds had been admin- 
istered repeatedly for 3 doses. Subsequently, the response to 
SKF-38393 was found to be greater than that seen in naive 
neonatal 6-OHDA-lesioned animals receiving their first dose of 
this D,-dopamine agonist. In addition, present data demon- 
strated that the responses to scopolamine and theophylline were 
greater in rats previously treated repeatedly with SKF-38393 
than in drug-naive neonatal 6-OHDA-lesioned rats. Even though 
amphetamine is dependent upon the release of dopamine from 
remaining terminals and is depressed following 6-OHDA le- 
sions, primed animals showed greater activity to amphetamine 
than unprimed animals. These data raise several questions. Be- 
cause d-amphetamine is an indirect-acting dopamine agonist, 
it is not known why the action of d-amphetamine is decreased 
in 6-OHDA-lesioned rats, whereas the action of scopolamine 
and theophylline is enhanced. This would suggest differing 
mechanisms by which the dopamine is released. Nonetheless, 
it is clear that endogenous release of dopamine can prime D,- 
dopamine receptor responses in neonatally lesioned rats and 
that previous repeated exposure to a D,-dopamine agonist can 
enhance the response of indirect-acting psychostimulants. Yet 
to be answered is whether endogenous release in unlesioned 
rats, if sufficiently intense, can have a similar effect on D,- 
dopamine receptor responsiveness (i.e., prime the response). In 
the present study, at the doses of SKF-38393 repeatedly ad- 
ministered systemically, or directly into brain, we were unable 
to demonstrate priming of D,-dopamine receptor responsive- 
ness in unlesioned rats. In fact, repeated administration of SKF- 
38393 produced a reduction in some behaviors in unlesioned 
rats, suggesting that tolerance was developing. Neither priming 
nor tolerance was observed in adult 6-OHDA-lesioned rats. We 
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presume that the proposed coupling of D,- and D,-dopamine 
receptors through intact catecholamine-containing neurons must 
account for these latter observations (Breese and Mueller, 1985; 
Breese et al., 1985b). 
Repeated administration of the indirect-acting dopamine ag- 
onists, d-amphetamine or cocaine, can result in behavioral su- 
persensitivity in unlesioned rats providing that sufficient time 
is allowed between administrations (Post, 1980; Robinson and 
Becker, 1986). Therefore, it would not be surprising to find a 
link between the elevated responses to these psychostimulants 
and priming of D,-dopamine receptor responses. However, this 
link has yet to be made, and the available data can be used to 
argue for and against such a relationship. There is one com- 
ponent of the priming of D,-dopamine receptor responses ob- 
served in our investigations that seems to differ from that ob- 
served with repeated administration of indirect-acting dopamine 
agonists. Some researchers have found that classical condition- 
ing to the testing environment is important to the enhanced 
sensitivity of d-amphetamine (Tilson and Rech, 1973) while 
others have shown behavioral supersensitivity to amphetamine 
in the absence of conditioning cues (Robinson, 1984; Coward, 
1986). The present study demonstrated that D,-dopamine-re- 
ceptor priming can be exhibited even when animals are re- 
peatedly dosed in an environment different from that in which 
the rats are finally tested (Table 2). This latter observation min- 
imizes the potential importance of conditioning to the priming 
of D,-dopamine receptor responses and could imply differences 
with the enhanced behavioral sensitivity observed after cocaine 
and d-amphetamine. It is apparent that the increasing sensitivity 
of D,-dopamine receptors with repeated administration is due 
to a change in postsynaptic responsiveness. If there is a change 
in D,-dopamine responsiveness with chronic administration of 
indirect-acting compounds, it would involve a presynaptic change 
in dopamine release, a postsynaptic supersensitivity, or both. 
Robinson and Becker (1986) reported in a recent review that 
presynaptic mechanisms are altered after chronic d-ampheta- 
mine, but only 8 of 20 studies were able to implicate a change 
in postsynaptic receptor sensitivity. A possible reason for the 
apparent absence of a change in postsynaptic responsiveness in 
these earlier studies may relate to the general use of apomor- 
phine to test for postsynaptic receptor sensitivity (Klawans and 
Margolins, 1975). Apomorphine at the doses tested in these 
investigations activates primarily D,-dopamine receptors (Breese 
et al., 1985b). In subsequent experiments, it would seem rea- 
sonable to determine D,-dopamine receptor sensitivity after 
chronic d-amphetamine treatment using a specific D,-dopamine 
agonist. However, it may be difficult to see a change in sensitivity 
after systemic administration of SKF-38393 in unlesioned rats. 
Future studies will have to resolve such difficulties before it can 
be determined whether the enhanced behavioral responses after 
repeated psychostimulant treatment are due to a change in D,- 
dopamine receptor sensitivity. 
Priming of the D,-dopamine receptor responsiveness in the 
neonatal 6-OHDA-lesioned rat represents a model of a long- 
term change in neural function associated with repeated acti- 
vation of a chemically defined receptor system. As such, the 
underlying neurochemical mechanisms that lead to this in- 
creased sensitivity may be representative of changes in other 
central processes requiring a “permanent” neural message. Re- 
lated areas might include learning, development of craving fol- 
lowing repeated intake of some drugs, or the appearance of 
motor disturbances following prolonged administration of drugs 
that influence dopamine receptor function. 
The neonatal 6-OHDA-lesioned rat is proposed to model the 
dopamine depletion seen in Lesch-Nyhan disease (Breese et al., 
1984). Thus, the endogenous release of dopamine from re- 
maining neurons in this syndrome could presumably sensitize 
D,-dopamine receptors, as was seen with the indirect-acting 
dopamine agonists in this investigation. However, there is no 
direct evidence that this is the case. It is our opinion that a 
stress component might be necessary for this to occur (i.e., stress- 
induced dopamine release). We have proposed that reduced 
adenosine seen in Lesch-Nyhan disease could facilitate central 
mechanisms resulting in dopamine release (Criswell et al., 1988). 
Nevertheless, based upon these present animal studies, priming 
of D,-dopamine receptor function could be an important com- 
ponent of the self-biting behavior observed in patients with 
Lesch-Nyhan disease (see also Breese et al., 1984, 1985b). The 
behavioral supersensitivity associated with the priming of 
D,-dopamine receptors is not associated with an increase in 
dopamine receptor number or affinity when evaluated with an- 
tagonist ligands (Breese et al., 1987; Duncan et al., 1987). Thus, 
the increased effectiveness of D,-dopamine receptor agonists 
after repeated administration must, presumably, be associated 
either with a change in second or third messengers linked to 
this receptor or with a change in a system or systems modulating 
dopamine-mediated effects. Future research will attempt to re- 
solve the neurochemical basis for this priming phenomenon. 
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